You're describing a molecule with a complex chemical name. Here's a breakdown of what it likely is and why it might be important in research:
**What it is:**
* **2-(1-benzo[e]benzofuranyl)-N-[4-methoxy-3-(4-morpholinylsulfonyl)phenyl]acetamide** is a synthetic organic compound.
* **Benzo[e]benzofuran:** This part refers to a specific fused ring system. Benzofuran itself is a ring structure containing a benzene ring (6-membered ring with alternating double bonds) and a furan ring (5-membered ring with an oxygen atom). The benzo[e] indicates how this system is fused onto another benzene ring.
* **Acetamide:** This is a simple amide group, a common functional group in organic chemistry.
* **N-[4-methoxy-3-(4-morpholinylsulfonyl)phenyl]:** This part describes a complex substituent attached to the nitrogen of the acetamide. Let's break it down:
* **4-methoxy:** A methoxy group (CH3O-) attached to the phenyl ring at the 4-position.
* **3-(4-morpholinylsulfonyl):** This is a longer group attached to the 3-position of the phenyl ring.
* **Morpholine:** A six-membered heterocyclic ring containing an oxygen and a nitrogen.
* **Sulfonyl:** A sulfur atom double-bonded to two oxygen atoms.
**Why it might be important in research:**
Without more specific context, it's difficult to say precisely why this compound is being researched. However, given its structure, it's likely related to:
* **Drug Discovery:** The presence of various functional groups (amides, sulfonyl, ether, etc.) suggests this compound could be a **potential drug candidate**.
* **Biological Activity:** Compounds with this type of structure often exhibit interesting biological activity (e.g., binding to proteins, enzymes, or receptors) which could be useful for treating diseases.
* **Materials Science:** This compound could be a **precursor or building block** for larger, more complex molecules used in materials development.
* **Organic Synthesis:** It might be a **synthetic intermediate** used in the preparation of other valuable compounds.
**To understand its specific research relevance, you'd need to:**
* **Know the research context:** What are the goals of the research project? What disease or problem is it addressing?
* **See the experimental details:** What tests and assays are being conducted with this compound? What biological targets or materials are being studied?
**If you have more information about the research project, please share it, and I can provide a more specific answer.**
ID Source | ID |
---|---|
PubMed CID | 3312717 |
CHEMBL ID | 1399744 |
CHEBI ID | 114899 |
Synonym |
---|
MLS000336616 |
smr000248228 |
CHEBI:114899 |
2-benzo[e][1]benzofuran-1-yl-n-(4-methoxy-3-morpholin-4-ylsulfonylphenyl)acetamide |
HMS2559D23 |
MLS003912259 |
chembl1399744 , |
bdbm50370165 |
Q27196742 |
2-(1-benzo[e]benzofuranyl)-n-[4-methoxy-3-(4-morpholinylsulfonyl)phenyl]acetamide |
Z28622906 |
AKOS034060346 |
736950-91-7 |
n-(4-methoxy-3-(morpholinosulfonyl)phenyl)-2-(naphtho[2,1-b]furan-1-yl)acetamide |
way-621001 |
Class | Description |
---|---|
naphthofuran | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 39.8107 | 0.0447 | 17.8581 | 100.0000 | AID485341 |
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 28.1838 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
Chain A, Cruzipain | Trypanosoma cruzi | Potency | 31.6228 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 13.4591 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
acid sphingomyelinase | Homo sapiens (human) | Potency | 14.1254 | 14.1254 | 24.0613 | 39.8107 | AID504937 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 29.0929 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
TDP1 protein | Homo sapiens (human) | Potency | 27.5110 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
67.9K protein | Vaccinia virus | Potency | 19.1180 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 35.4813 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 17.7828 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 31.6228 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 20.5962 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 75.6863 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
geminin | Homo sapiens (human) | Potency | 22.7265 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
lamin isoform A-delta10 | Homo sapiens (human) | Potency | 35.4813 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Sphingomyelin phosphodiesterase | Homo sapiens (human) | IC50 (µMol) | 14.1254 | 5.0000 | 5.3000 | 5.6000 | AID1357899 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
sphingomyelin phosphodiesterase activity | Sphingomyelin phosphodiesterase | Homo sapiens (human) |
protein binding | Sphingomyelin phosphodiesterase | Homo sapiens (human) |
zinc ion binding | Sphingomyelin phosphodiesterase | Homo sapiens (human) |
hydrolase activity, acting on glycosyl bonds | Sphingomyelin phosphodiesterase | Homo sapiens (human) |
phosphatidylcholine phospholipase C activity | Sphingomyelin phosphodiesterase | Homo sapiens (human) |
acid sphingomyelin phosphodiesterase activity | Sphingomyelin phosphodiesterase | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
extracellular space | Sphingomyelin phosphodiesterase | Homo sapiens (human) |
lysosome | Sphingomyelin phosphodiesterase | Homo sapiens (human) |
extracellular space | Sphingomyelin phosphodiesterase | Homo sapiens (human) |
lysosome | Sphingomyelin phosphodiesterase | Homo sapiens (human) |
endosome | Sphingomyelin phosphodiesterase | Homo sapiens (human) |
lipid droplet | Sphingomyelin phosphodiesterase | Homo sapiens (human) |
plasma membrane | Sphingomyelin phosphodiesterase | Homo sapiens (human) |
endolysosome | Sphingomyelin phosphodiesterase | Homo sapiens (human) |
lamellar body | Sphingomyelin phosphodiesterase | Homo sapiens (human) |
lysosomal lumen | Sphingomyelin phosphodiesterase | Homo sapiens (human) |
extracellular exosome | Sphingomyelin phosphodiesterase | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID1357899 | Inhibition of acid sphingomyelinase in human HuH7 cell lysate using NBD-sphingomyelin as substrate after 30 mins by TLC based fluorescence assay | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | Discovery of N-hydroxy-3-alkoxybenzamides as direct acid sphingomyelinase inhibitors using a ligand-based pharmacophore model. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 4 (66.67) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.35) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |